Meet Our Founders

Tobias Ripsom

CEO & Cofounder
Toby directs GALYNA’s plant powered solutions into the skin care universe. As the co-founder of Veritas Fine Cannabis, Colorado’s original craft cannabis, Toby had a front row seat to the first adult-use legalization of cannabis and hemp. In that era, the power of superiorly cultivated trees, and their magical budding flowers was all encompassing. Seeing this, he began to cobble together concepts friendlier to the masses yet still rooted in his gardens. It was clear, the game changing plant matter he processed everyday could also be a packaged good.

After suffering from a lifetime of troubled skin and now aging out of its resiliency, he partnered with topical industry veteran Frank Fanning to dabble with benchtop prototypes. Toby’s fascination with real results from illicit ingredients grew irresistible. Never satisfied with the proof behind claims, nor touch and feel of dispensary offerings versus what he saw in department store skin care, he set out to prove cannabinoids benefited everybody.

Toby brought almost a decade of operational, financial and marketing management prowess from real estate related endeavors to the cultivation arena of Denver circa 2014. His company helped pioneer America’s first legal marketplace and legitimize the alternative vice through professional trust and best in class craftsmanship. Nearly a decade later, he is still learning daily how plant power can improve lives and bodies, then turning that knowledge into the next skin solution.

A one-time competitive nordic ski racer for both the Sun Valley Ski Education Foundation and University of New Hampshire Wildcats, he can still be found testing GALYNA formulations, both before, during and after endless high-altitude kilometers. A husband and father of two sons, he and his family reside in greater Denver, Colorado.

Dr. Marnie Peterson

Chief Scientific Officer

Dr. Marnie Peterson is an entrepreneur, innovator, and expert in infectious diseases. She has over 25 years of experience in the discovery and development of new therapeutics related to infectious diseases and wound healing.

In 2016, she founded and became the CEO of Jackson, Wyoming-based Extherid Biosciences to focus on new approaches to preclinical research, including live animal alternatives (ex vivo tissue models) that aim to accelerate and predict clinical outcomes.